title: Successful management of imatinib despite alopecia and nail necrosis.
abstract: Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature.
authors: Celal Bayar University, Medical Faculty, Department of Hematology, Turkey.
authors: Ulku
authors: U
authors: Ergene
authors: Demircan
authors: D
authors: Ozbalci
mesh_terms: D000505:Alopecia / Q000139:chemically induced / Q000473:pathology; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D010304:Paronychia / Q000139:chemically induced / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate